PCSK9 Inhibitors [PCSK9 inhibitory]
topical
249
- Terms
-
inhibitory PCSK9
kardiovaskulární inhibitory PCSK9
kardiovaskulární PCSK9 inhibitory
-
PCSK9 Inhibitors Cardiovascular
PCSK9 Inhibitors, Cardiovascular
Persistent link
https://www.medvik.cz/link/D000091362
Definition
Agents that inhibit Proprotein Convertase Subtilisin/Kexin Type 9 (see PROPROTEIN CONVERTASE 9 (PCSK9)), an enzyme that plays an important role in the degradation of the LDL receptors. It favors LDL catabolism and reduces plasma LDL-cholesterol (LDL_C) level.
- DUI
- D000091362 MeSH Browser
- CUI
- M000748765
- Previous indexing
- Anticholesteremic Agents (2018-2021)
- History note
- 2022
- Public note
- 2022
Allowable subheadings
- AD
- administration & dosage 17
- AE
- adverse effects 7
- AN
- analysis
- BL
- blood
- CF
- cerebrospinal fluid
- CS
- chemical synthesis
- CH
- chemistry
- CL
- classification 1
- EC
- economics 3
- HI
- history
- IM
- immunology
- IP
- isolation & purification
- ME
- metabolism
- PK
- pharmacokinetics
- PD
- pharmacology 28
- PO
- poisoning
- RE
- radiation effects
- ST
- standards
- SD
- supply & distribution
- TU
- therapeutic use 50
- TO
- toxicity
- UR
- urine
...
Occurrences in Medvik records